Home
HomeChat
Markets
AlertsCalendarScreenerCharts
Portfolio
WatchlistsPortfolioFiles
Account
Docs
Sign upJoinLog inLogin

Capricor Therapeutics, Inc. (CAPR) stock profile

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, has completed a Phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD) and is in a Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003, which is in pre-clinical development for the treatment of trauma-related injuries and conditions, as well as two vaccine candidates in development for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

Key facts

SymbolCAPR
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology
CEOLinda Marbán
Employees231
HeadquartersSan Diego, CA, US
IPO2007-02-13
Websitewww.capricor.com

Explore CAPR on Vantafin

  • Capricor Therapeutics, Inc. Overview
  • Capricor Therapeutics, Inc. Financials
  • Capricor Therapeutics, Inc. News
  • Capricor Therapeutics, Inc. Events
  • Capricor Therapeutics, Inc. SEC filings
  • Capricor Therapeutics, Inc. Insider transactions
  • Capricor Therapeutics, Inc. Transcripts

Frequently asked questions

What does Capricor Therapeutics, Inc. (CAPR) do?
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, has completed a Phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD) and is in a Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003, which is in pre-clinical development for the treatment of trauma-related injuries and conditions, as well as two vaccine candidates in development for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Where is CAPR stock listed?
Capricor Therapeutics, Inc. trades under the ticker CAPR on NASDAQ.
How can I research CAPR's financials and filings?
Vantafin provides Capricor Therapeutics, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the CAPR profile.